Centre of Genomics and Policy, McGill University, Montreal, Canada; Ulm University and Ulm University Medical Center, Ulm, Germany.
Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong S.A.R, China; Ulm University and Ulm University Medical Center, Ulm, Germany.
CRISPR J. 2022 Apr;5(2):203-212. doi: 10.1089/crispr.2021.0094. Epub 2022 Mar 22.
Currently, most advances in site-specific epigenetic editing for human use are concentrated in basic research, yet, there is considerable interest to translate this technology beyond the bench. This review highlights recent developments with epigenetic editing technology in comparison with the canonical CRISPR-Cas genome editing, as well as the epistemic and ethical considerations with preemptive translation of epigenetic editing into clinical or commercial use in humans. Key considerations in safety, equity, and access to epigenetic editing are highlighted, with a spotlight on the ethical, legal, and social issues of this technology in the context of global health equity.
目前，大多数用于人类的靶向表观遗传学编辑技术的进展都集中在基础研究领域，然而，人们有很大的兴趣将这项技术从实验室推向临床应用。本综述重点介绍了表观遗传学编辑技术与经典的 CRISPR-Cas 基因组编辑技术的最新进展，以及将表观遗传学编辑技术预先转化为临床或商业应用于人类所涉及的认识论和伦理问题。重点强调了表观遗传学编辑的安全性、公平性和可及性方面的关键问题，并特别关注了这项技术在全球健康公平背景下的伦理、法律和社会问题。
